Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.
Also called NCT02192424
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 109 participants
- Registry
-
NCT02192424
-
- Other papers using this trial's data
- Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02192424. Randomized; single masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2020-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)
- Acronym
- RESET-IT
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin alone
- Intervention (Drug)
- Metformin + Intermittent Insulin Therapy
- Lead sponsor
- Mount Sinai Hospital, Canada
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct02192424- Content hash
96e7b3dbe21d198ea37c1dff8f436a9b622725aa7a7883e4c1fcae3a68b53d53